Stockreport

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]

Cerevel Therapeutics Holdings, Inc.  (CERE) 
PDF Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional [Read more]